Upcoming educational meetings, including #DCLung26, are set to feature updates on topics like ROS1 NSCLC. Recent patient-focused discussions at the #ALKSummit26 centered on managing side effects and improving quality of life for patients with ALK-positive lung cancer.
“Join us in Washington, DC on Saturday, October 10 for #DCLung26 - a one-day, comprehensive, multidisciplinary, discussion-based lung cancer CME update! Dr. @JessicaJLinMD will give us her perspective on ROS1 NSCLC and new agents that will impact care!”
— @StephenVLiu · Upcoming CME Event · View post ↗
“How do we live well w ALK+#lungcancer? Our Board Member @Yvonne_Diaz_ Diaz hosted this convo today w Dr @ShirishGadgeel, @DrYolaOLO & members of the ALK community. An honest conversation about side effects, quality of life & what matters most to us.”
— @ALKPositiveinc · Patient Quality of Life · View post ↗The single-arm, phase II DARVIN trial evaluating dalpiciclib plus endocrine therapy in HR+/HER2- advanced breast cancer with visceral crisis showed a median PFS of 11.2 months. An IPTW-adjusted external comparison against chemotherapy found a PFS benefit (11.2 vs 4.6 months; HR 0.30), though these findings from a nonrandomized study are considered hypothesis-generating.
“This strengthens the case that selected patients with HR+/HER2− visceral crisis may not automatically require chemotherapy.”
— @DrRishabhOnco · CDK4/6i in visceral crisis · View post ↗
“Case-by-case discussion = clinical pearls you can use TODAY.”
— @HemOncMiami · Clinical education · View post ↗A prospective study in localized pancreatic ductal adenocarcinoma found circulating KRAS tumor DNA was detectable at diagnosis, after neoadjuvant chemotherapy, and after surgical resection. Separately, a real-world analysis is evaluating ctDNA in patients with curatively resected stage I-III biliary tract cancer. The GI oncology community is also reviewing Total Neoadjuvant Therapy (TNT) strategies in rectal cancer.
“Real-world analysis of ctDNA and other biomarkers in patients with curatively resected stage I-III biliary tract cancer - ESMO Gastrointestinal Oncology”
— @Erman_Akkus · ctDNA in Biliary Tract Cancer · View post ↗“🏥TNT strategies in rectal cancer”
— @Erman_Akkus · Rectal Cancer Treatment · View post ↗
“In a prospective study of localized pancreatic ductal adenocarcinoma, circulating KRAS tumor DNA was detectable at diagnosis, after neoadjuvant chemotherapy, and after surgical resection.”
— @AnnalsofSurgery · ctDNA in Pancreatic Cancer · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
A multicenter study of deferred consolidative nephrectomy in over 200 RCC patients after IO-based therapy found a 13% pathological complete response rate and 100% 18-month PFS. Separately, a single-center radiomics study developed a dual-energy CT model to predict high- versus low-grade NMIBC pre-resection, achieving an AUC of 0.89.
“13% w/ pCR, and 100% 18-month PFS.”
— @paulosiqamaral · Deferred Consolidative Nephrectomy · View post ↗
“Can a dual-energy CT call a bladder tumor's grade before resection? This model reaches AUC 0.89 for high- vs low-grade NMIBC.”
— @katy_beckermann · Bladder Cancer Radiomics · View post ↗
“mtDNA alterations are far more common than I realized in RCC. How will we be able to leverage this therapeutically?”
— @rmelias2 · mtDNA in RCC · View post ↗New International Myeloma Working Group (IMWG) recommendations for solitary plasmacytomas highlight a 50% risk of progression to symptomatic myeloma within 5 years after local radiotherapy. In related diseases, a pooled analysis of BCMA-targeted therapies in relapsed/refractory AL Amyloidosis showed cardiac responses in 41% of evaluable patients. Research on CAR-T kinetics found cilta-cel expansion is greater than ide-cel's, with rapid peak expansion correlating with delayed neurotoxicity.
“Note the 50% risk of progression to symptomatic myeloma within 5 years after initial definitive local radiotherapy.”
— @Myeloma_Doc · Solitary Plasmacytoma · View post ↗
“✅ Cardiac responses occurred in 41% of evaluable patients (BsAb highest at 49%), and renal responses in 30% overall”
— @HadidiSamer · BCMA Therapies in AL Amyloidosis · View post ↗
“✅Rapid peak cilta-cel expansion correlates with delayed NT”
— @SurbhiSidanaMD · CAR-T Kinetics and Toxicity · View post ↗“MRD dynamics predicts progression (pts w/ volatile results & those w/ primarily & resurgent MRD resistance had dismal survival) and reveals a vulnerable state for immunotherapy interception in myeloma w/ BCMA CAR-T cells:”
— @Myeloma_Doc · MRD Dynamics Post-CAR-T · View post ↗A retrospective cohort study comparing front-line treatments for Burkitt lymphoma found that DA-EPOCH-R resulted in the best EFS and OS versus GMALL high-intensity therapy. Separately, a survey is circulating within the hematology community to establish a physician benchmark for evaluating AI in hematologic malignancies.
“Best EFS and OS for DA EPOCH R in ND Burkitt lymphoma >>> Comparison of outcomes after DA-EPOCH-R or GMALL high-intensity therapy for front-line treatment of Burkitt lymphoma: A retrospective cohort”
— @smbenlazar · Burkitt Lymphoma · View post ↗
“Should AI be judged on straightforward guideline-based questions—or on the cases where even experts thoughtfully disagree?”
— @YLeyfman · AI in Hematology · View post ↗